Single site, prospective, comparative effectiveness pilot trial comparing efficacy and safety outcomes of three embolic materials (particles, liquid embolics, and Wallaby Phenox coils) in MMA embolication for cSDH.
Adult patients (≥ 18 years)
Undergoing Middle Meningeal Artery Embolization (MMAE) for chronic subdural hematoma (cSDH)
Able to provide informed consent or have a legally authorized representative (LAR) do so
Ineligible for MMAE procedure, as deemed by the treating physician, for any indication (e.g. pregnancy)
Non-chronic subdural hematoma (cSDH) indications for Middle Meningeal Artery Embolization (MMAE), including acute subdural hematoma with symptom onset < 72 hours or mixed acute/chronic without predominant chronic features
Pregnancy or breastfeeding
Known severe allergy or contraindication to embolic materials (e.g. particles, liquids like Onyx/n-BCA, or coils)
Sanford Health
Lead sponsor
phenox Inc.
Collaborator